CoChat

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

Open access
Meier, Juris J., Nauck, Michael A. · 2010 · Diabetes

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes is characterized by a deficit in β-cell mass, impaired insulin secretion in response to various stimuli (1–3), as well as a variable extent of insulin resistance (4). More specifically, regarding β-cell function, a significant reduction of the incretin effect, i.e., the postprandial augmentation of insulin secretion by gut hormones, has been described in patients with type 2 diabetes (5). Thus, while the two incretin hormones gastric inhibitory polypeptide (glucose-dependent insulinotopic polypeptide [GIP]) and glucagon-like peptide 1 (GLP-1) are held responsible for ∼50–70% of the postprandial insulin responses in healthy individuals (6), their contribution to the overall insulin responses after oral glucose ingestion may amount to <20% in patients with type 2 diabetes (5,7). The reasons underlying the loss of incretin activity in type 2 diabetes are still incompletely understood. The present article reviews the available evidence regarding disturbances in the enteroinsular axis in patients with type 2 diabetes and provides possible explanations for their etiologies, focusing on the personal experience of the authors. ### Secretion of incretin hormones in patients with type 2 diabetes. Because the incretin effect has been related to the secretion and insulinotropic action of GIP and GLP-1 (8,9), it was obvious to compare these parameters between patients with type 2 diabetes and healthy control subjects: Regarding the secretion of GIP, elevated, normal, and reduced plasma levels have been described in patients with type 2 diabetes (10–15). However, taking together all the evidence available, the secretion of GIP appears to be relatively unchanged in type 2 diabetic patients. For GLP-1 release, the case is even more complex. Several studies have reported significant reductions in GLP-1 levels after mixed meal ingestion in patients with type 2 diabetes (10,16,17). In addition, one study has found minor impairments in GLP-1 levels in individuals with impaired glucose …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-1899

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Relationship between the glucose concentrations at fasting (A) and 120 min after the ingestion of 75 g oral glucose (B) and the respective integrated GLP-1 levels measured over 240 min after oral glucose ingestion in 14 nondiabetic individuals (blue), 17 people with impaired glucose tolerance or impaired fasting glucose (green), and 17 patients with type 2 diabetes (red). Individual data were taken from ref. 11. r2 and P values were calculated by linear regression analyses. NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.
FIG. 1. Relationship between the glucose concentrations at fasting (A) and 120 min after the ingestion of 75 g oral glucose (B) and the respective integrated GLP-1 levels measured over 240 min after oral glucose ingestion in 14 nondiabetic individuals (blue), 17 people with impaired glucose tolerance or impaired fasting glucose (green), and 17 patients with type 2 diabetes (red). Individual data were taken from ref. 11. r2 and P values were calculated by linear regression analyses. NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.CC BY-NC-ND · PubMed Central
FIG. 2. Hypothetical impact of a general impairment in β-cell function on the incretin effect: In individuals with a normal insulin secretory capacity, an oral glucose load elicits a much greater insulin secretory response than an intravenous (i.v.) glucose load. With a decreasing β-cell secretory capacity, the insulin response to the oral glucose load is relatively more diminished than the insulin response to intravenous glucose infusion. By these means, the incretin effect, i.e., the difference in the insulin responses to oral and intravenous glucose, diminishes with declining β-cell function. For details, see text.
FIG. 2. Hypothetical impact of a general impairment in β-cell function on the incretin effect: In individuals with a normal insulin secretory capacity, an oral glucose load elicits a much greater insulin secretory response than an intravenous (i.v.) glucose load. With a decreasing β-cell secretory capacity, the insulin response to the oral glucose load is relatively more diminished than the insulin response to intravenous glucose infusion. By these means, the incretin effect, i.e., the difference in the insulin responses to oral and intravenous glucose, diminishes with declining β-cell function. For details, see text.CC BY-NC-ND · PubMed Central
FIG. 3. Relationship between the relative percentage contribution of the incretin effect on the overall insulin responses after oral glucose ingestion and to the respective fasting glucose concentrations in 48 individuals with and without diabetes. Individual data were taken from refs. 35 and 7. The solid line denotes the regression line calculated by regression analyses in relation to the upper and lower 95% CIs.
FIG. 3. Relationship between the relative percentage contribution of the incretin effect on the overall insulin responses after oral glucose ingestion and to the respective fasting glucose concentrations in 48 individuals with and without diabetes. Individual data were taken from refs. 35 and 7. The solid line denotes the regression line calculated by regression analyses in relation to the upper and lower 95% CIs.CC BY-NC-ND · PubMed Central
FIG. 4. A: Relationship between the plasma insulin levels during the intravenous (i.v.) administration of glucose alone and the insulin levels during the combined administration of i.v. glucose and GIP in 27 healthy control subjects, 27 first-degree relatives of patients with type 2 diabetes, 13 women with previous gestational diabetes, and 10 patients with type 2 diabetes. Individual data were taken from refs. 29, 35, and 37. B: Relationship between the plasma insulin levels during the intravenous administration of GIP and glucose and the insulin levels measured 30 min after oral ingestion of 75 g glucose in 54 healthy control subjects, 44 first-degree relatives of patients with type 2 diabetes, and 20 women with previous gestational diabetes. Individual data were taken from refs. 32 and 37. The solid line denotes the regression line calculated by regression analyses in relation to the upper and lower 95% CIs.
FIG. 4. A: Relationship between the plasma insulin levels during the intravenous (i.v.) administration of glucose alone and the insulin levels during the combined administration of i.v. glucose and GIP in 27 healthy control subjects, 27 first-degree relatives of patients with type 2 diabetes, 13 women with previous gestational diabetes, and 10 patients with type 2 diabetes. Individual data were taken from refs. 29, 35, and 37. B: Relationship between the plasma insulin levels during the intravenous administration of GIP and glucose and the insulin levels measured 30 min after oral ingestion of 75 g glucose in 54 healthy control subjects, 44 first-degree relatives of patients with type 2 diabetes, and 20 women with previous gestational diabetes. Individual data were taken from refs. 32 and 37. The solid line denotes the regression line calculated by regression analyses in relation to the upper and lower 95% CIs.CC BY-NC-ND · PubMed Central
FIG. 5. Intracellular actions of GIP and GLP-1 on the β-cell. Several cellular functions are affected: closing of the ATP-dependent potassium channel (1); calcium influx in response to action potentials (2); release of calcium from intracellular stores (3); and the readiness with which insulin storage granules are released (4), probably depending on protein phosphorylation. These effects are tightly linked to the glucose-dependent generation of ATP, meaning that GLP-1 and GIP augment insulin release only in the presence of hyperglycemia. For details, see ref. 74.
FIG. 5. Intracellular actions of GIP and GLP-1 on the β-cell. Several cellular functions are affected: closing of the ATP-dependent potassium channel (1); calcium influx in response to action potentials (2); release of calcium from intracellular stores (3); and the readiness with which insulin storage granules are released (4), probably depending on protein phosphorylation. These effects are tightly linked to the glucose-dependent generation of ATP, meaning that GLP-1 and GIP augment insulin release only in the presence of hyperglycemia. For details, see ref. 74.CC BY-NC-ND · PubMed Central
FIG. 6. Relationship between the relative increase in insulin secretion during the intravenous administration of GIP at hyperglycemic clamp conditions and the respective fasting glucose concentrations in 93 individuals with and without diabetes. The relative increments in insulin secretion were expressed in relation to the mean values obtained in the individuals with normal glucose concentrations (fasting glucose levels <100 mg/dl). Individual data were taken from refs. 29, 30, and 35. The solid line denotes the regression line calculated by nonlinear regression analyses using an exponential decay function.
FIG. 6. Relationship between the relative increase in insulin secretion during the intravenous administration of GIP at hyperglycemic clamp conditions and the respective fasting glucose concentrations in 93 individuals with and without diabetes. The relative increments in insulin secretion were expressed in relation to the mean values obtained in the individuals with normal glucose concentrations (fasting glucose levels <100 mg/dl). Individual data were taken from refs. 29, 30, and 35. The solid line denotes the regression line calculated by nonlinear regression analyses using an exponential decay function.CC BY-NC-ND · PubMed Central
FIG. 7. Working model for the diminished incretin effect in type 2 diabetes: The reduction in β-cell mass (A) leads to a significant impairment in the maximum insulin secretory capacity of the β-cells (D). The reduced secretory capacity leads to a preferential impairment of the relative insulin response to oral glucose, whereas a relatively normal insulin response to intravenous glucose (a comparably weaker β-cell stimulus) can still be maintained. The defects in β-cell function and the impaired incretin effect (B) lead to chronic hyperglycemia (E), which may diminish GLP-1 secretion (F) and impair GIP action through GIP-receptor downregulation (C), thereby further diminishing the incretin effect. Genetic factors may independently modify β-cell mass and function as well as GLP-1 secretion. Dashed lines in D, E, and F indicate the respective patterns typical of patients with type 2 diabetes, solid lines show the respective normal patterns. The dashed line in B illustrates the insulin levels after oral glucose ingestion; the solid line shows the respective patterns after isoglycemic intravenous glucose administration.
FIG. 7. Working model for the diminished incretin effect in type 2 diabetes: The reduction in β-cell mass (A) leads to a significant impairment in the maximum insulin secretory capacity of the β-cells (D). The reduced secretory capacity leads to a preferential impairment of the relative insulin response to oral glucose, whereas a relatively normal insulin response to intravenous glucose (a comparably weaker β-cell stimulus) can still be maintained. The defects in β-cell function and the impaired incretin effect (B) lead to chronic hyperglycemia (E), which may diminish GLP-1 secretion (F) and impair GIP action through GIP-receptor downregulation (C), thereby further diminishing the incretin effect. Genetic factors may independently modify β-cell mass and function as well as GLP-1 secretion. Dashed lines in D, E, and F indicate the respective patterns typical of patients with type 2 diabetes, solid lines show the respective normal patterns. The dashed line in B illustrates the insulin levels after oral glucose ingestion; the solid line shows the respective patterns after isoglycemic intravenous glucose administration.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 5

  1. Meier, 2005, Insulin secretion, 961
  2. Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (Abstract), Diabetologia, 19, 271
  3. Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes, Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
  4. Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
  5. Pfeifer, 1981, Insulin secretion in diabetes mellitus, Am J Med, 70, 579, 10.1016/0002-9343(81)90579-9 · DOI · Paper page

Cited by

Items 101–200 of 215

Metadata

Authors
Meier, J. J., & Nauck, M. A.
Affiliations
  • St. Josef-Hospital (DE)
  • Diabeteszentrum Bad Lauterberg (DE)
Corresponding author
Meier, Juris J.
Venue
Diabetes
Published
2010-05-01
Volume
59
Issue
5
Pages
1117-1125
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2097621088
Cited by
215
References
72
Citations by year
2026: 4 · 2025: 5 · 2024: 14 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 15 · 2018: 8 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 27 · 2012: 19
FWCI
3.41
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, incretin effect, enteroinsular axis, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin secretion, postprandial insulin secretion, beta-cell mass, insulin resistance
MeSH terms
Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Models, Biological, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.